Happify launches Ensemble DTx for depression, anxiety in USHappify Health has launched a prescription digital therapeutic (DTx) – called Ensemble – that can assist the treatment Share XHappify launches Ensemble DTx for depression, anxiety in UShttps://pharmaphorum.com/news/happify-launches-ensemble-dtx-for-depression-anxiety-in-us/
Digital mental health specialist Woebot raises $90mInvestments in digital health firms are running high at the moment, and a $90 million round for four-year-old Share XDigital mental health specialist Woebot raises $90mhttps://pharmaphorum.com/news/digital-mental-health-specialist-woebot-raises-90m/
Sage/Biogen’s zuranolone works in depression, but maybe not enoughSage Therapeutics and Biogen’s antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a Share XSage/Biogen’s zuranolone works in depression, but maybe not enoughhttps://pharmaphorum.com/news/sage-biogens-zuranolone-works-in-depression-but-maybe-not-enough/
Study finds “alarming” hike in antidepressant costs during COVID-19Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in Share XStudy finds “alarming” hike in antidepressant costs during COVID-19https://pharmaphorum.com/news/study-finds-alarming-hike-in-antidepressant-costs-during-covid-19/
Small Pharma stock market launch funds DMT-based depression drug trialUK-based Small Pharma has launched on the Toronto’s TSX Venture Exchange, raising 58 million Canadian dollars (around £34m) Share XSmall Pharma stock market launch funds DMT-based depression drug trialhttps://pharmaphorum.com/news/small-pharma-launches-on/
Magic mushroom compound matches antidepressant in clinical trialThe active compound in magic mushrooms – psilocybin – seems to be at least as effective as a Share XMagic mushroom compound matches antidepressant in clinical trialhttps://pharmaphorum.com/news/magic-mushroom-compound-matches-antidepressant-in-clinical-trial/
Tribunal maintains Lexon’s £1.2m fine for breaking competition lawPharmaceutical wholesaler Lexon (UK) has lost its appeal against a £1.2 million fine in a case that accused Share XTribunal maintains Lexon’s £1.2m fine for breaking competition lawhttps://pharmaphorum.com/news/tribunal-maintains-lexons-1-2m-fine-for-breaking-competition-law/
Otsuka, Click trial digital depression therapy with GoogleOtsuka and Click Therapeutics are working with Verily, the healthcare subsidiary of Google owners Alphabet, on a fully Share XOtsuka, Click trial digital depression therapy with Googlehttps://pharmaphorum.com/news/otsuka-click-trial-digital-depression-therapy-with-google/
Novartis buys neurology biotech Cadent for up to $770mNovartis is to buy neuroscience drugs firm Cadent Therapeutics in a deal worth up to $770 million. The Share XNovartis buys neurology biotech Cadent for up to $770mhttps://pharmaphorum.com/news/novartis-buys-neurology-biotech-cadent-for-up-to-770m/
